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Abstract
This study investigated the actin scavenger function of the vitamin D binding protein (DBP) in
vivo using DBP null (−/−) mice. Intravenous injection of G-actin into wild-type (DBP+/+) and
DBP−/− mice showed that contrary to expectations, DBP+/+ mice developed more severe acute
lung inflammation. Inflammation was restricted to the lung and pathological changes were clearly
evident at 1.5 and 4 hours post-injection but were largely resolved by 24 hours. Histology of DBP
+/+ lungs revealed noticeably more vascular leakage, hemorrhage and thickening of the alveolar
wall. Flow cytometry analysis of whole lung homogenates showed significantly increased
neutrophil infiltration into DBP+/+ mouse lungs at 1.5 and 4 hours. Increased amounts of protein
and leukocytes were also noted in bronchoalveolar lavage fluid from DBP+/+ mice 4 hours after
actin injection. In vitro, purified DBP-actin complexes did not activate complement or neutrophils
but induced injury and death of cultured human lung microvascular endothelial cells (HLMVEC)
and human umbilical vein endothelial cells (HUVEC). Cells treated with DBP-actin showed a
significant reduction in viability at 4 hours, this effect was reversible if cells were cultured in fresh
media for another 24 hours. However, a 24-hour treatment with DBP-actin complexes showed a
significant increase in cell death (95% for HLMVEC, 45% for HUVEC). The mechanism of
endothelial cell death was via both caspase-3 dependent (HUVEC) and independent (HLMVEC)
pathways. These results demonstrate that elevated levels and/or prolonged exposure to DBP-actin
complexes may induce endothelial cell injury and death, particularly in the lung microvasculature.
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INTRODUCTION
Actin is the most abundant and highly conserved protein inside all eukaryotic cells and
exists in two forms: monomeric globular actin (G-actin) and polymerized filamentous actin
(F-actin) (Rottner and Stradal, 2011). During tissue injury large quantities of actin can be
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released into extracellular fluids where the ionic conditions and lack of regulators favor
spontaneous generation of F-actin filaments (Janmey and Lind, 1987). Circulating F-actin
potentially is injurious and previous animal studies have shown that intravascular actin
filaments can trigger angiopathic consequences in the microcirculation similar to fibrin
(Haddad, et al., 1990, Meier, et al., 2006). Accordingly, higher organisms have evolved a
robust extracellular actin scavenger system (EASS) consisting of two plasma proteins:
gelsolin that caps and severs F-actin filaments, and the vitamin D binding protein (DBP) that
binds G-actin monomers tightly for subsequent clearance from the blood (Meier, et al.,
2006). Circulating DBP-actin complexes have been observed in both humans and animals
following traumatic injury, and the plasma concentration of actin-free DBP has been shown
to be an effective but indirect marker of tissue injury in cases of severe trauma (Antoniades,
et al., 2007, Meier, et al., 2006, Schiodt, et al., 2007). Plasma levels of actin-free DBP below
3.5 μM (200 μg/ml) have been shown to significantly correlate with poor prognosis in
human cases of sepsis, multiple trauma and acetaminophen-induced liver failure
(Antoniades, et al., 2007, Dahl, et al., 2003, Meier, et al., 2006, Schiodt, et al., 2007).
Clinical outcome and decreased plasma levels of DBP in trauma have a statistical correlation
similar to the APACHE II score, Kings College criteria and the TRISS-like method
(Antoniades, et al., 2007, Dahl, et al., 2003, Meier, et al., 2006, Schiodt, et al., 2007). Thus,
the capacity to scavenge extracellular actin is a physiologically important role for this
multifunctional plasma protein.
DBP, also referred to as Gc-globulin, is an abundant (6–7 μM) 56 kDa plasma protein that is
part of the albumin gene family and shares the multiple disulfide linked triple domain
structure of albumin (Chun, 2012). As its name implies, it is the primary extracellular
transport protein for all vitamin D metabolites. Besides the vitamin D and actin binding
functions, DBP can serve as a neutrophil chemotactic cofactor, and a deglycosylated form of
DBP acts as a macrophage activating factor (Chun, 2012). There are no known natural
deficiencies of DBP in any vertebrate species but a DBP null (−/−) mouse, fully backcrossed
on a C57BL/6 background, has been generated. These mice are healthy and develop and
reproduce similar to their wild-type counterparts when fed a vitamin D sufficient mouse
chow diet (Safadi, et al., 1999, White, et al., 2002). Studies using DBP−/− mice have shown
that the primary role of DBP is to maintain circulating vitamin D levels within a
physiological range to protect against transient vitamin deficiencies (Zella, et al., 2008).
More recently, our lab has shown that DBP−/− mice have significantly reduced (~50%)
neutrophil recruitment to the lungs compared to their wild-type DBP+/+ counterparts in
three different alveolitis models, two acute and one chronic (Trujillo, et al., 2013). However,
the actin scavenger function of DBP has not been investigated in vivo using DBP null mice,
and the objective of this study was to characterize how mice with a systemic deficiency of
DBP respond to actin in the circulation. Contrary to expectations, results show that DBP−/−
mice developed much less acute lung inflammation than their wild-type DBP+/+
counterparts when actin was injected intravenously. Moreover, in vitro studies showed that
DBP-actin complexes induce endothelial cell injury and death. These studies suggest that
elevated levels and/or prolonged exposure to DBP-actin complexes in vivo may contribute
to the sequelae of traumatic tissue injury.
MATERIALS AND METHODS
Reagents
Purified human DBP was obtained from Athens Research & Technology (Athens, GA). The
IgG fraction of goat polyclonal anti-human DBP was purchased from DiaSorin (Stillwater,
MN) and then affinity-purified in our lab using immobilized DBP. Highly purified rabbit
skeletal muscle actin was obtained from Cytoskeleton, Inc. (Denver, CO). Goat polyclonal
anti-actin (I-19) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and
Ge et al. Page 2
Immunobiology. Author manuscript; available in PMC 2015 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
monoclonal pan anti-actin mAb (ACTN05) was purchased from Thermo Scientific/Lab
Vision (Fremont, CA). Polyclonal anti-gelsolin (ab74420) was obtained from Abcam
(Cambridge, MA). Sterile, endotoxin-free HBSS, DPBS and RPMI 1640 were purchase
from Mediatech, Inc. (Manassas, VA). EDTA solution was purchased from Life
Technologies-Gibco (Grand Island, NY). Collagenase and DNase I were purchased from
Roche (Indianapolis, IN). Rat anti-mouse monoclonal antibodies for flow cytometry and
their corresponding labeled isotype controls, were all purchased from Biolegend (San Diego,
CA): PE-labeled anti Gr-1 (RB6-8C5), FITC-labeled anti-F4/80 (BM8). Purified cobra
venom factor (CVF) and sheep erythrocytes were obtained from Complement Technology,
Inc. (Tyler, TX). Rabbit anti-sheep erythrocyte antibody was purchased from Dako
(Accurate Scientific Westbury, NY). Mouse monoclonal anti-human factor B (clone D33/3)
was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Purified human TNF-α and
IL-1β were purchased from R&D Systems (Minneapolis, MN). Bio-Plex 23-mouse cytokine
panel was obtained from BioRad (Hercules, CA).
DBP+/+ and −/− mouse colonies
The DBP−/− mouse line has been fully backcrossed on a C57BL6/J background for 11
generations. A detailed description of the DBP−/− and the corresponding DBP+/+ mouse
colonies, produced from DBP+/− hemizygotes, has been recently published (Trujillo, et al.,
2013). In some experiments, wild type C57BL6/J mice were purchased from Jackson Labs
(Bar Harbor, ME). Only mature male age-matched mice (age ranged from 10 weeks to 10
months) were utilized and all animals were housed in a maximum isolation facility at Stony
Brook University. Animal experiments were performed using protocols approved by the
Institutional Animal Care and Use Committee at Stony Brook University.
Intravenous administration of G-actin
Highly purified rabbit skeletal muscle actin was reconstituted using sterile pyrogen-free
DPBS at 1 mg/ml under aseptic conditions. DBP+/+ and −/− mice were injected with 100 μl
of G-actin (1 mg/ml) via the tail vein to introduce an actin bolus into the circulation. The
control group received 100 μl of DBPS via the tail vein. The mice were observed for signs
of respiratory distress. After 1.5, 4 or 24 hours, groups of mice were anesthetized by an i.p.
injection (0.3 ml) of ketamine (90 mg/kg) and xylazine (10 mg/kg) solution. Following
anesthesia, EDTA plasma was obtained by retro-orbital bleeding and mice were then
euthanized by cervical dislocation and secured to a small animal surgery board (Kent
Scientific, Torrington, CT). A small midline incision was made in the suprasternal region
and the trachea was exposed by blunt dissection. A sterile BD angiocath (18 gauge needle
stylet in a 1.3×44 mm long I.V. catheter) was inserted into the anterior portion of the
exposed trachea between cartilage rings and the lungs were lavaged once and the BAL fluid
was stored on ice until analyzed for total protein and cell count. BAL fluid was centrifuged
at 200 × g for 5 min at 4°C to pellet the cells. BAL cells pellets were resuspended in 1 ml of
PBS-1% BSA and duplicate counts of total cell number were made using a BioRad TC10
automated cell counter. The protein concentration of the BAL supernatant was measured
using a Lowry Protein Assay.
Preparation of organs for histology
In a separate group of mice that were not lavaged, the mouse lungs were inflated with 10%
PBS-buffered formalin for 15 min at 25 cm water pressure to ensure the proper degree of
lung inflation. The lungs were removed from the thoracic cavity en bloc with the heart and
submerged in 10% PBS-buffered formalin for 24 hours at 4°C. The kidneys, and livers were
also isolated and submerged into formalin. The fixed organs were transferred to the Stony
Brook University Hospital Histology Laboratory for preparation of thin-sectioned slides
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stained with hematoxylin and eosin (H&E). Digital photos were taken using a Nikon Eclipse
Ti inverted microscope with an Insight Spot2 digital camera using 20x and 100x objectives.
Preparation of lung homogenates
Single cell suspensions were prepared from whole lung homogenates at each time point after
actin injection. Lungs were isolated and placed into a well in 24-well plate containing 1 ml
of complete culture medium (RPMI 1640 + 10% FBS) and thoroughly minced into small
pieces using surgical scissors. The minced tissue was transferred to a 15 ml conical tube
containing 5 ml of fresh collagenase solution (1 mg/ml type IV collagenase, 25 U/ml DNase
I, 5% FBS and the volume adjusted up to 5 ml with RPMI). The samples were then
incubated at 37°C for 45 minutes with shaking. After the incubation, the tissue was
disaggregated into a cellular suspension by passing it through an 18-gauge needle 20 times.
The samples were centrifuged at 500 × g for 5 minutes. The supernatant was aspirated and
the pellet was resuspended in RBC lysis buffer and immediately centrifuged (50 × g for 5
minutes). The supernatant was saved and the pellet, containing large tissue aggregates, was
discarded. The supernatant was then again centrifuged at 500 × g for 5 min and the cells
were resuspended in 500 μl of flow cytometry staining buffer. The samples were counted
using an automated cell counter and then stained for Gr-1 and F4/80 and analyzed by flow
cytometry.
Nondenaturing PAGE and immunoblot analysis for DBP-actin complexes
EDTA plasma was diluted 1:2 in DPBS and 50 μl of the diluted plasma was loaded to 10%
native (no SDS) polyacrylamide gel. After separation proteins were transferred to PVDF
membranes (Millipore, MA). The membrane was probed for DBP-actin complexes using
1:1000 dilution of polyclonal goat anti-human DBP (which strongly reacts with mouse
DBP) followed by 1:5000 HRP-conjugated donkey anti-goat secondary antibody. The blot
was developed with HyGlo Quick spray chemiluminescent HRP antibody detection reagent
(Denville Scientific Inc., South Plainfield, NJ) and visualized by autoradiography film.
Endothelial cell culture
Human lung microvascular endothelial cells (HLMVEC) and endothelial cell growth media
kits (CC-3156 & CC-4176) were obtained from Lonza (Walkersville, MD). HLMVEC were
obtained at passage 3 and immediately thawed and cultured in endothelial growth medium-2
(EGM-2) Bulletkit at 5000 cells/cm2 in a T25 flask. The medium was changed the next day
and subsequently every other day until cells were 70 to 80% confluent. HLMVECs were
detached using Lonza sub-culturing reagents and the viability was determined by trypan
blue assay. Human umbilical cord endothelial cells (HUVECs) were freshly isolated and
generously provided by Dr. Martha Furie, Stony Brook University. These cells were grown
in the same media as HLMVEC to 70 to 80% confluence.
Cell viability assay
Cell titer blue (CTB) viability assay was obtained from Promega (Madison, WI). Endothelial
cells were cultured to 70 to 80% confluence and harvested as described above. 5000 cells in
100 μl of EGM2 complete medium were seeded to 96 well plates and incubated at 37°C, 5%
CO2 incubator overnight for the cells to attach. The cells were treated for 4 hours or 24
hours and CTB reagent was added at the end of the treatment. Cells with CTB reagent were
incubated for 2 hours and the fluorescent intensity was then measured at 560 nm excitation
and 590 nm emission.
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Nuclear staining to evaluate cell death
Acridine orange (AO) and ethidium bromide (EB) were purchased from Fisher Scientific
(Fairlawn, NJ). Endothelial cells were harvested at 70 to 80% confluence and seeded in 48
well plates at 2 × 105 cells/well and incubated overnight for the cells to attach. AO/EB
solution was prepared at 100 μg/ml of each reagent. Cells were then treated for 24 hours
with DBP-actin then each sample was stained with 100 μl of AO/EB solution just prior to
microscopy and quantification. At least 300 cells were counted for each treatment and the
percent of dead (red-orange nucleus) and live (green nucleus) cells was calculated.
Immunoblot for cleaved PARP
Rabbit antibody to the cleaved form of poly ADP ribose polymerase (PARP, #Asp214) was
purchased from Cell Signaling Technology (Danvers, MA). Endothelial cells were cultured
to 70 – 80% confluence then harvested and seeded into 6 well plates at 106 cells/ml. Cells
were incubated overnight to allow attachment and then were treated for 24 hours. After the
treatment period cells were washed with DBPS 3 times and then detached. Whole cell
lysates were obtained using lysis buffer containing 100 mM Tris pH 7.4, 150 mM NaCl, 1.0
mM EDTA pH 8.0, 1% Triton X-100, 10% glycerol and a complete protease inhibitor
cocktail tablet (Millipore). The protein concentration in the cell lysate was determined by a
protein assay and 50 μg total protein was loaded on 10% SDS-PAGE. After separation the
proteins were transferred to PVDF membranes (Millipore, MA). The PVDF membrane was
probed with a 1:500 dilution of the cleaved PARP antibody followed by an HRP-conjugated
goat anti-rabbit IgG. The blot was developed with HyGlo Quick spray chemiluminescent
HRP antibody detection reagent and visualized by autoradiography film.
Measurement of serum complement activation
The effect of DBP-actin complexes on serum complement was evaluated using a hemolytic
assay to test for classical or lectin pathway activation, and an immunoblot for factor B
cleavage to assess alternative pathway activation. The hemolytic was performed using
antibody-coated sheep erythrocytes (EA) as the target cell for lysis by serum complement.
Sheep erythrocytes were obtained from Complement Technology, Inc. (Tyler, TX). Normal
human serum with a defined hemolytic value was purchased as lyophilized powder from
Sigma-Aldrich (St. Louis, MO). Rabbit anti-sheep erythrocyte antibody was purchased from
Dako (Accurate Scientific Westbury, NY). Normal human serum was treated with from 10
nM to 1500 nM of actin or DBP-actin complexes for 1 hour at 37°C. An aliquot (10 μl) of
the treated serum was mixed with EA and incubated for 30 min at 37°C. The samples were
centrifuged and the red blood cell lysis was measured by reading the absorbance at 412 nm
for the release hemoglobin. Water lysed EA were used as a positive control. The data were
presented as percentage of hemolysis.
DBP-actin treated serum was also separated using 10% SDS-PAGE and blotted onto a
PVDF membrane. The blot was probed with mouse monoclonal anti-human factor B (clone
D33/3) primary antibody followed by a goat anti-mouse HRP-conjugated secondary
antibody. The blot was developed using HyGlo Quick spray chemiluminescent HRP
antibody detection reagent and visualized by autoradiography film. The cleavage of factor B
is readily observed by the disappearance of the native 100 kDa factor B band and the
appearance of the cleavage product, 33 kDa Ba fragment. The positive control for alternative
pathway activation was CVF-treated serum.
Neutrophil chemotaxis assay
Measurement of cell movement of normal human neutrophils and differentiated HL-60 cells
was performed using a 48 well microchemotaxis chamber as previously described in detail
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(Trujillo, et al., 2011). Human neutrophils were isolated from the venous blood of healthy
medication-free volunteers who gave informed consent using a standard 3-step purification
protocol (Trujillo, et al., 2011). The human promyelocytic cell line HL-60 was also used and
differentiated for 4 days using 1.3% DMSO to obtain a neutrophil-like phenotype (Hauert, et
al., 2002). In each assay, the migration of 200,000 cells (50 μl of 4×106/ml) was evaluated.
Cell movement was quantitated microscopically by measuring the distance in microns (μm)
that the leading front of cells had migrated into the filter according to the method described
by Zigmond and Hirsch (Zigmond and Hirsch, 1973). In each experiment, five fields per
duplicate filter were measured at 400× magnification.
Measurement of reactive oxygen species
Detection of cellular reactive oxygen species (ROS) in neutrophils and endothelial cells was
performed using the 2',7'-dichlorofluorescein diacetate (DCFDA) reagent as part of a kit
purchased from Abcam (ab112851, Cambridge, MA). Primary human neutrophils were
freshly isolated as described above and 4 × 106 cells were used per sample. Endothelial cells
were grown to 70 – 80% confluence and 1.5 × 105 cells per well were seeded into 96 well
plates and allowed to adhere for 24 hours before treatment. Cells were stained with 20 μM
of DCFDA for 30 min at 37°C. Neutrophils were then treated with 50 μM tert-butyl
hydrogen peroxide (TBHP, the positive control), 1 μM PMA, 1 μM DBP, 1 μM actin, and 1
μM DBP-actin for 1 hour at 37°C. Endothelial cells were treated with 50 μM TBHP, EGM-2
media, 1 μM DBP, 1 μM actin or 1 μM DBP-actin for 24 hours. The fluorescence intensity
was then measured at 485 nm excitation and 535 nm emission.
Statistical analysis
A minimum of 5 mice were used for each experimental treatment, and at least 3 experiments
were performed for each in vitro analysis. Statistical differences between the mean values of
the treatment groups were evaluated using either an unpaired T-test (comparing two groups)
or analysis of variance (ANOVA) followed by a multiple comparisons post-hoc test
(comparing three or more groups). Statistical analysis was performed using the software
program InStat (GraphPad Software, San Diego, CA).
RESULTS
DBP is the primary scavenger for extracellular actin released from dead or damaged cells,
and this function was investigated in vivo using mice with a systemic deficiency of DBP.
Both wild-type (DBP+/+) and DBP null (DBP−/−) mice were injected with 100 μg of
purified rabbit skeletal actin via the tail vein and then sacrificed after either 1.5, 4 or 24
hours. None of the mice in either group showed signs of overt respiratory distress and
displayed normal behavior following actin injection. At the indicated time points, blood,
lungs, heart, liver and kidneys were collected to assess the effect of circulating DBP-actin
complexes. Plasma samples were analyzed using non-denaturing gels to verify formation of
DBP-actin complexes in the blood. Figure 1A demonstrates that, as expected, DBP-actin
complexes are observed only in wild-type (DBP+/+) mice. Analysis of the blots by
densitometry revealed that the greatest amount of complexes were observed after 1.5 hours
(78%) and then declined to about 50% at 4 hours and 30% at 24 hours (Fig. 1B).
Furthermore, both DBP+/+ and −/− mice had approximately the same amount of total
gelsolin in plasma (Fig. 1C), indicating that DBP−/− mice did not have a compensatory
increase in the other plasma EASS protein.
The amount of circulating DBP-actin complexes (Fig. 1A) paralleled the degree of lung
inflammation (Fig. 2), where DBP+/+ mice showed extensive interstitial edema and
hemorrhage at 1.5 hours that was decreased after 4 hours and largely resolved 24 hours after
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actin injection. In contrast, DBP−/− mice showed almost no histological signs of
inflammation at 1.5 hours, mild inflammation at 4 hours that was noticeably less than the
DBP+/+ group (Fig. 2). Histological evidence of lung inflammation in both DBP+/+ and −/−
mice was considerably decreased at 24 hours (Fig. 2). The insets in the lower left of each
panel are high magnification (1000×) images of the same lung section to show better the
degree of cellularity. Interestingly, the lung was the only organ that showed inflammatory
injury after intravenous actin injection; the heart, liver and kidneys all appeared essentially
identical to the PBS controls (data not shown). The degree of lung inflammation was
quantitated by measuring the number of Gr1+ neutrophils by flow cytometry (gating shown
in Fig. 3A) in lung homogenates 1.5, 4 or 24 hours after actin injection (Fig. 3B). Both
groups showed that largest number of neutrophils after 4 hours that decreased by 24 hours
(Fig. 3B). There was also significantly reduced numbers of lung neutrophils in the DBP−/−
group at the 1.5 and 4 hour time points (Fig. 3B). In contrast, there was no difference in the
number of F4/80+ macrophages in lung homogenates of DBP+/+ versus DBP−/− mice (Fig.
3C).
The pulmonary capillary bed is the first microvasculature that an intravenous injected
protein complex would encounter. Injury to the capillary endothelium can induce
permeability changes and provoke inflammation of the airspaces (alveolitis). To determine if
circulating DBP-actin complexes can also induce an alveolitis, bronchoalveolar lavage
(BAL) was performed in DBP+/+ and −/− mice at the peak of inflammation, i.e., 4 hours
after intravenous injection of actin (Fig. 4). Figure 4A shows that actin injection induced
significant protein leakage into the airspaces of DBP+/+ mice that was not observed in DBP
−/− animals. Analysis of stained cytospin slides of the BAL fluid showed that DBP+/+ mice
also had a significant increase in the number of leukocytes in the alveolar spaces compared
to the DBP−/− group (Fig. 4B). The preceding experiments demonstrate that DBP-actin
complexes are associated with acute lung inflammation that is largely resolved by 24 hours.
Therefore, the possible effects of DBP-actin complexes on triggering immediate
inflammatory mechanisms were investigated next. DBP-actin complexes do not activate the
complement system, a potent source of early-acting mediators in blood (Supplemental
Figure 1). In addition, complexes are not chemotactic for human neutrophils (Supplemental
Fig. 2A) and do trigger generation of reactive oxygen species in these cells (Supplemental
Fig. 2B). Finally, there were no differences between DBP+/+ and −/− mice in the levels of
23 inflammatory cytokines (Bio-Plex 23 panel mouse cytokine assay) measured in the BAL
4 hours after injection of DBP-actin complexes (data not shown).
The observed lung inflammation presented above (Figs. 2–4) would be consistent with
alterations to lung microvascular endothelial cells. Thus, the possibility that DBP-actin
complexes have a direct effect on endothelial cells was investigated next in vitro. Primary
human endothelial cells from the microvasculature of an adult lung (HLMVEC) and from an
umbilical cord (HUVEC) were treated with DBP alone, actin alone or DBP-actin complexes
for 4 hours at 37°C and the effect was assessed using the cell-titer blue (CTB) viability assay
(Fig. 5). HLMVEC treated with DBP-actin showed a significantly reduced viability
compared to untreated cells, DBP treated or actin treated cells (Fig. 5A). The effect of serum
starvation is shown as the positive control for reduced cell viability (Fig. 5A). HUVECs are
more robust cells and showed increased viability in response to these treatments as
compared to HLMVECs, but there was still a significant reduction in viability with DBP-
actin treatment (Fig. 5B). A similar reduction in cell viability with DBP-actin treatment was
also observed using primary human neonatal dermal endothelial cells (data not shown). The
morphology of DBP-actin treated endothelial cells by phase contrast microscopy show that
HLMVECs are retracted and partially rounded-up (Supplemental Figure 3), similar results
were also noted with HUVECs (data not shown). To determine if damage is reversible, cells
were treated with DBP-actin complexes for 4 hours then either washed and placed in fresh
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media for a 24 hour recovery period or tested immediately using the CTB assay. Figure 6
shows that the injurious effects of a 4 hour DBP-actin treatment were fully reversible in both
HLMVECs (Fig. 6A) and HUVECs (Fig. 6B).
The aforementioned cell viability and morphology data would indicate that DBP-actin
complexes directly induce endothelial cell injury. To determine if prolonged treatment can
cause cell death, primary endothelial cells were treated for 24 hours with DBP-actin
complexes and then stained with acridine orange and ethidium bromide to determine the
percent live/dead cells. The nucleus of live cells stains green with acridine orange whereas
dead cells take up ethidium bromide and display a red or orange nucleus. This assay was
quantified by counting the number of dead and live cells in multiple fields. Figure 7A
demonstrates that DBP-actin complexes induce the same degree of HLMVEC cell death as
the positive control (serum starvation), and significantly less than untreated or single treated
(DBP alone, actin alone) cells. Figure 7B shows that HUVECs are more resistant to the
injurious effects of DBP-actin complexes or serum starvation, but still display a significant
decrease in the number of live cells following a 24 hour treatment.
The kinetics of endothelial cell injury and death following treatment with DBP-actin
complexes would be consistent with an apoptotic mechanism. Therefore, potential
mechanisms of cell death were next investigated by examining the cleavage of PARP, a key
substrate in the caspase-3 dependent apoptosis pathway. Cell lysates of HLMVECs and
HUVECs treated with DBP-actin were blotted with a specific antibody that only detects
cleaved PARP. HLMVECs showed no PARP cleavage with 24 hour treatment (Fig. 8A),
despite the fact that these cells showed clear morphological signs of injury and death (Fig.
7A and Supplemental Fig. 3). In contrast, HUVECs displayed a dramatic increase in the
amount of cleaved PARP after a 24 hour treatment with DBP-actin complexes (Fig. 8B)
indicating a robust activation of the caspase-3 dependent apoptosis pathway. One
mechanism to trigger an apoptotic pathway in endothelial cells is by generation of
intracellular reactive oxygen species, however, DBP-actin complexes did not increase the
amount of intracellular oxidants in HLMVECs over untreated control cells (Supplemental
Figure 4). These results indicate that DBP-actin complexes can directly trigger endothelial
cell death by both caspase 3-dependent and independent pathways.
Finally, because endothelial cells are very sensitive to the effects of lipopolysaccharide
(LPS), we considered the possibility that the pure actin and DBP used in the above in vitro
assays may be contaminated with LPS. Both DBP and actin were purchased as lyophilized
powders that were reconstituted with sterile endotoxin-free reagents using aseptic technique
in a laminar flow BSL-2 cabinet. All subsequent experiments were performed with
endotoxin-free reagents in a sterile laminar flow hood. In addition, experiments were
performed where polymyxin B (that binds and neutralizes LPS) was added to purified DBP
and this treatment did not reduce the effect of DBP-actin complexes on endothelial cells.
Thus, we conclude that the reagents most likely were not contaminated with LPS and the
results were due to the direct effect of DBP-actin complexes on endothelial cells.
DISCUSSION
Massive tissue injury triggered by burns, sepsis or severe trauma will result in the release of
large amounts of actin into extracellular fluids. Indeed, previous studies in humans and
animals have shown significant quantities of DBP-actin in the plasma following injury
(Antoniades, et al., 2007, Dahl, et al., 1998, Dahl, et al., 2003, Harper, et al., 1987, Lind SE,
1986, Meier, et al., 2006, Schiodt, et al., 2007, Young, et al., 1987). The role of DBP-actin
complexes as potential mediators of tissue injury has received little attention, presumably
because they are cleared rapidly from the circulation largely by the liver (Meier, et al.,
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2006). In contrast, the role of actin-free DBP has been the focus of several studies in both
humans and animals where low plasma DBP levels have been shown to significantly
correlate with poor prognosis in human cases of sepsis, multiple trauma and acetaminophen-
induced liver failure (Antoniades, et al., 2007, Dahl, et al., 2003, Meier, et al., 2006,
Schiodt, et al., 2007). The assumption in these studies is that when a large percentage of the
circulating DBP pool is consumed (i.e., bound to G-actin and cleared from the blood) there
is very little remaining DBP to neutralize actin released from ongoing injury. Thus, a
reduced level of unbound DBP facilitates formation of actin filaments that then induce
microvascular damage and tissue ischemia. However, the inverse of this premise is that large
amounts of DBP-actin complexes can trigger tissue injury, and this alternative hypothesis
has not been investigated. The present study is the first to utilize the DBP null mouse to
evaluate the role of DBP-actin complexes in vivo. If the prevailing hypothesis is correct that
maintaining a critical concentration of free DBP in blood is essential to protect against the
damaging effects of extracellular actin, then a systemic deficiency of DBP should be lethal
when actin is injected intravenously. Results presented herein demonstrate that a deficiency
of DBP protects the lung against the injurious effects of intravascular actin. Moreover,
purified DBP-actin complexes mediate endothelial cell injury and death in vitro.
Remarkably the DBP−/− mice were refractory to lung inflammation induced by intravenous
injection of actin. It is highly unlikely that the differences in actin-induced inflammation
observed between DBP+/+ and −/− mice are due to strain variations, other than a systemic
lack of DBP, since the DBP−/− mice were backcrossed for 11 generations on a C57BL/6J
background and both the DBP+/+ and −/− colonies were bred from the same founder
hemizygotes (DBP+/−) (Trujillo, et al., 2013). Moreover, the DBP−/− mice do not have an
increase in plasma gelsolin, the other EASS protein in blood, to compensate for the lack of
DBP (Fig. 1C). Previous studies have shown that plasma gelsolin, much like DBP, becomes
depleted during traumatic tissue injury (Dahl, et al., 1999). Nevertheless, plasma gelsolin in
DBP−/− mice may help to limit actin filament formation by capping/binding F-actin and
possibly weak binding of G-actin monomers (Lee and Galbraith, 1992), thus preventing
obstruction of the lung microvasculature. But the EASS role of gelsolin in DBP−/− mice
remains to be investigated. The results reported herein also confirm our recent study where
we demonstrated that a systemic deficiency of DBP reduces inflammation and neutrophil
recruitment to the lungs in acute and chronic models of alveolitis (Trujillo, et al., 2013).
Thus, although our current and previous mouse studies would suggest that a lack of DBP is
beneficial, a deficiency of DBP may be detrimental in certain infectious and inflammatory
conditions. For example, DBP deficiency could enhance lethality in acute bacterial
infections where inflammation and a critical tissue concentration of neutrophils are needed
for bacterial clearance. However, these models need to be investigated using the DBP−/−
mouse.
The mechanism by which DBP-actin complexes trigger lung inflammation in vivo and
endothelial injury in vitro is not known. The possibility that complexes could trigger rapid
inflammatory mechanisms, such as complement and/or neutrophil activation, was
investigated and found to be negative (supplemental figures 1 and 2). Also, DBP-actin
complexes did not increase cytokine levels in the BAL 4 hours after actin injection.
However, in vivo, DBP-actin complexes induced pulmonary interstitial edema, hemorrhage
(Fig. 2) and a permeability leak into the airspaces (Fig. 4A), indicating an effect on the lung
microvasculature. In vitro, short-term exposure (4 hours) of endothelial cells to purified
DBP-actin complexes induced reversible injury (Figs. 5 and 6) whereas longer exposure (24
hours) resulted in cell death (Fig. 7). These results are consistent with a mechanism that
would require either a critical threshold concentration and/or exposure time to induce cell
injury. Varying levels of DBP-actin complexes are continually formed in vivo as a result of
minor tissue trauma, menstrual cycles, infections or surgery. Therefore, low levels of
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circulating DBP-actin would be inconsequential. On the other hand, high concentrations of
DBP-actin in blood could act as a danger signal of ongoing and significant tissue injury.
Indeed, a large percentage (78%) of the total plasma DBP pool was bound to actin 1.5 hours
after injection in DBP+/+ mice (Fig. 1A). This percentage is similar to a previous study
examining fulminant hepatic necrosis (FHN) in humans where 72% of plasma DBP was
complexed with actin in patients who died of the disease whereas only 22% of total DBP
was bound to actin in FHN survivors (Goldschmidt-Clermont, et al., 1988).
Although the mechanism by which DBP-actin triggers endothelial cell injury is not known,
this study provides potential avenues for further investigation. First, results clearly
demonstrate that a caspase-3 dependent apoptotic pathway is activated in HUVECs treated
with DBP-actin (Fig. 8B). In contrast, HLMVECs showed no cleaved PARP in response to
DBP-actin treatment (Fig. 8A), perhaps indicating that an alternative cell death pathway is
triggered in HLMVECs. Furthermore, studies have shown that endothelial cells from
different organs can respond differently to the same stimulus. For example, large vessel
endothelial cells such as HUVECs are more sensitive to ionophore (A2318) induced calcium
toxicity and apoptotic death than microvascular endothelial cells (Kelly, et al., 1998). This
could explain the differences in PARP cleavage between HUVECs and HLMVECs. Yet
both of these primary endothelial cells are sensitive to injury and death when treated with
DBP-actin in vitro. Indeed, a major focus of future studies will be to determine the cell
surface ligand for DBP-actin complexes on endothelial cells. Previous reports from our lab
and others have shown that unbound DBP binds with low avidity to multiple cell surface
macromolecules such as chondroitin sulfate proteoglycans (DiMartino and Kew, 1999),
CD44 (McVoy and Kew, 2005), megalin (Nykjaer, et al., 1999), and cubulin (Nykjaer, et al.,
2001). However, it is not known if actin alters the binding of DBP to the cell surface and/or
its preference of a cellular ligand.
A major limitation of this study is the method of inducing injury in mice, i.e., a single
intravenous bolus of purified actin. A more physiological approach would be to employ a
model that has continuous injury over a period of hours to days, such as the cardiotoxin-
induced muscle necrosis model (Deponti, et al., 2007). In addition, including DBP+/− mice
in this study would have provided valuable information on how mice respond to
extracellular actin with half-normal levels of circulating DBP. Our previous report showed
that DBP+/− mice respond to a C5a-induced alveoltis essentially the same as wild-type DBP
+/+ mice (Trujillo, et al., 2013), but how DBP+/− mice would respond to a bolus of
intravenous actin is not known. Nevertheless, this report clearly demonstrates that DBP-
actin is a mediator of inflammation, and possibly tissue injury, and this knowledge may
change the current paradigm that focuses on the concentration of actin-free DBP in plasma
as the important prognostic indicator in traumatic injury. The information from this study
also may be consequential for the proposed efforts to infuse purified DBP intravenously into
trauma patients to augment their actin-free DBP levels as a potential supportive therapy
(Pihl, et al., 2010). Results from the mouse experiments reported herein would suggest that
approach could be detrimental.
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Abbreviations used in the paper
AO/EB acridine orange/ethidium bromide
BAL bronchoalveolar lavage
CTB cell-titer blue viability assay
DBP vitamin D binding protein
DCFDA 2',7'–dichlorofluorescein diacetate
EA antibody-coated sheep erythrocytes
EASS extracellular actin scavenger system
EGM-2 endothelial growth medium-2
HLMVEC human lung microvascular endothelial cell
HUVEC human umbilical vein endothelial cell
PARP poly ADP ribose polymerase
ROS reactive oxygen species
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Figure 1.
Plasma DBP-actin complexes and gelsolin levels in DBP+/+ and DBP−/− mice following
intravenous actin injection. (A) DBP immunoblot of EDTA plasma samples from three DBP
+/+ wild-type (WT) mice and three DBP−/− (KO) mice each obtained 1.5, 4 and 24 hours
after actin injection. Plasma aliquots were separated using a 10% native (non-denaturing) gel
then blotted for DBP. The electrophoretic separation of unbound DBP and DBP-actin
complexes is shown. (B) Densitometry measurement of DBP-actin complexes in panel A.
Data is presented as mean ± SEM (n = 3) of DBP-actin as a percent of total DBP (unbound
+ DBP-actin) in WT plasma. Statistical significance is indicated. (C) Gelsolin immunoblot
of plasma separated by SDS-PAGE from three DBP−/− (KO) and two DBP+/+ (WT) mice.
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Figure 2.
Histology of acute lung inflammation in DBP+/+ and DBP−/− mice 1.5, 4 and 24 hours after
intravenous injection of 100 μg purified rabbit skeletal muscle actin in a total volume of 100
μl. Images in all panels are H&E stained sections at 200× magnification, bar = 100 μm. Inset
panel is a 1000× magnification of that lung section.
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Figure 3.
Analysis of total neutrophils and macrophages in whole lung homogenates 1.5, 4 and 24
hours after intravenous injection of purified actin. (A) Flow cytometry gating for analyzing
neutrophils and macrophages in whole lung homogenates. A total of 104 cells were collected
and the forward scatter (FSC) and side scatter (SSC) gates set to exclude dead cells and
debris (left panel). Neutrophils were gated as the Gr-1 PE high, side scatter high cell
population (center panel). Macrophages were gated as F4/80-FITC high, Gr-1 PE low
population. (B) The percent of Gr-1+ neutrophils in lung homogenates measured by flow
cytometry. (C) The percent of F4/80+ macrophages in lung homogenates measured by flow
cytometry. Numbers represent mean% ± SEM (n= 5), statistical significance is indicated.
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Figure 4.
Analysis of total protein and leukocytes in BAL 4 hours after actin injection. (A) Total
protein content of cell-free BAL fluid from actin injected DBP+/+ mice (n = 6), actin
injected DBP−/− mice (n = 7) and PBS injected mice (n = 5). Statistical significance is
indicated. (B) Total BAL leukocytes from actin injected DBP+/+ and DBP−/− mice (n = 5).
Numbers represent mean ± SEM, statistical significance is indicated.
Ge et al. Page 16
Immunobiology. Author manuscript; available in PMC 2015 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5.
CTB viability assay of HLMVECs and HUVECs treated with DBP-actin complexes. (A)
HLMVECs. (B) HUVECs. Endothelial cells were treated for 4 hours with either EGM-2
growth medium (untreated = negative control), EGM-2 base medium without serum (starved
= positive control), or 1 μM of the indicated purified proteins in EGM-2 growth medium.
CTB reagent was added to the wells at 20 μl/well. Cells were incubated for 1 hour with CTB
reagent and the fluorescent intensity was measured at 560 nm excitation and 590 nm
emission. Numbers represent mean ± SEM (n = 3), statistical significance is indicated.
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Figure 6.
CTB viability assay to test reversible injury in HLMVECs and HUVECs treated with DBP-
actin complexes. HLMVECs (A) and HUVECs (B) were treated for 4 hours with either
EGM-2 growth medium (untreated = negative control), EGM-2 base medium without serum
(starved = positive control), or 1 μM of the indicated purified proteins in EGM-2 growth
medium (black bars). A duplicate set of cells were washed after the 4 hour treatment and
allowed to recover in EGM-2 growth medium for an additional 24 hours (gray bars). CTB
reagent was added to the wells at 20 μl/well. Cells were incubated for 1 hour with CTB
reagent and the fluorescent intensity was measured at 560 nm excitation and 590 nm
emission. Numbers represent mean ± SEM (n = 3). Triple asterisk indicates that the values
of DBP-actin treated cells and serum starved cells were significantly lower (P < 0.001) than
all other groups.
Ge et al. Page 18
Immunobiology. Author manuscript; available in PMC 2015 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 7.
Acridine orange and ethidium bromide nuclear staining of HLMVECs (A) and HUVECs (B)
after 24 hours of DBP-actin treatment. Cells were treated with EGM-2 growth medium,
serum started, 1 μM DBP, 1 μM actin or 1 μM DBP-actin complex for 24 hours. Cells were
stained with AO/EB and the percentage of live cells was quantified by counting at least 300
cells per treatment. Statistical significance is indicated.
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Figure 8.
Immunoblot for cleaved PARP in HLMVECs and HUVECs after 24 hours of DBP-actin
treatment. (A) HLMVECs were treated with EGM-2 growth medium, serum started, 1 μM
DBP, 1 μM actin or 1 μM DBP-actin complex. (B) HUVECs were treated with EGM-2
growth medium, 3% hydrogen peroxide (H2O2), 10 nM TNF-α, 10 nM IL-1β, 10 nM TNF-α
+IL-1β, 1 μM DBP, 1 μM Actin, and 1 μM DBP-Actin complex. Cell lysates were separated
on 10% SDS-PAGE gel and blotted for cleaved PARP. GAPDH is shown as a loading
control.
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